Previous 10 | Next 10 |
Verastem ([[VSTM]] +15.7%) has risen sharply during intraday trading after the company announced the FDA’s Breakthrough Therapy designation it received for the combination of VS-6766 and defactinib for the treatment of all patients with recurrent low-grade serous ovarian canc...
Shares of Verastem Inc. (NASDAQ:VSTM) traded today at $3.48, eclipsing its 52-week high. This new high was reached on below average trading volume as 249,000 shares traded hands, while the average 30-day volume is approximately 2.1 million shares. Verastem Inc. (NASDAQ:VSTM) defies analy...
Verastem's (VSTM) VS-6766 has received Breakthrough Therapy designation from the FDA for low-grade serous ovarian cancer.The designation is for a combination of the RAF/MEK inhibitor with the FAK inhibitor defactinib, which is also under development by the company.The combination is curr...
Verastem Inc. (NASDAQ:VSTM) traded at a new 52-week high today of $3.29. So far today approximately 209,000 shares have been exchanged, as compared to an average 30-day volume of 2.1 million shares. Verastem Inc. (NASDAQ:VSTM) is currently priced 9.6% above its average consensus analyst ...
Verastem (VSTM): Q1 Non-GAAP EPS of -$0.07; GAAP EPS of -$0.09 in-line.Revenue of $1.01M (-80.0% Y/Y)Verastem Oncology ended the first quarter 2021 with cash, cash equivalents and investments of $127.1 million.Guidance: With the proceeds from the sale of COPIKTRA, Verastem Oncology expects th...
Updated Phase 1/2 Data in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Continues to Demonstrate Activity, Durability and a Favorable Tolerability Profile for VS-6766 + Defactinib Combination Two Registration-Directed Phase 2 Trials Underway in LGSOC and KRAS G12V Non-Smal...
Top Penny Stocks for Your Wednesday Watchlist Making a penny stock watchlist ? There are a few things that you should consider. The first and arguably the most important is what’s going on in the world. Geopolitical and economic factors can greatly affect all industries as we...
Gainers: [[ANPC]] +32.0%. [[KLDO]] +3.4%. [[EBON]] +3.3%. [[VYGR]] +3.1%. [[RAIL]] +2.6%.Losers: [[CGEN]] -2.7%. [[RXRX]] -2.6%. [[CLPS]] -2.3%. [[LIZI]] -2.1%. [[VSTM]] -1.9%. For further details see: ANPC, KLDO, CGEN and CLPS among after-hours movers
Verastem monetised its approved asset Copiktra and now has a decent cash runway. Last year, it acquired new assets that it is running through trials. Trial completion is 3-4 years away. For further details see: Verastem: New Assets, New Indications
An update on the 20 life sciences companies Numenor Capital has profiled so far range from cell therapy companies like SQZ Biotech and Orchard Therapeutics to biologics platforms like Pandion. The best performing investment, over 170% return, so far has been Pandion Therapeutics that ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
24.23%Change Percent:
Verastem Inc. Company Name:
VSTM Stock Symbol:
NASDAQ Market:
Verastem Inc. Website:
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of it...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants t...